The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
Open accessAbstract
BACKGROUND: Long-acting beta-agonists and inhaled corticosteroids are used to treat chronic obstructive pulmonary disease (COPD), but their effect on survival is unknown. METHODS: We conducted a randomized, double-blind trial comparing salmeterol at a dose of 50 microg plus fluticasone propionate at a dose of 500 microg twice daily (combination regimen), administered with a single inhaler, with placebo, salmeterol alone, or fluticasone propionate alone for a period of 3 years. The primary outcome was death from any cause for the comparison between the combination regimen and placebo; the frequency of exacerbations, health status, and spirometric values were also assessed. RESULTS: Of 6112 patients in the efficacy population, 875 died within 3 years after the start of the study treatment. All-cause mortality rates were 12.6% in the combination-therapy group, 15.2% in the placebo group, 13.5% in the salmeterol group, and 16.0% in the fluticasone group. The hazard ratio for death in the combination-therapy group, as compared with the placebo group, was 0.825 (95% confidence interval [CI], 0.681 to 1.002; P=0.052, adjusted for the interim analyses), corresponding to a difference of 2.6 percentage points or a reduction in the risk of death of 17.5%. The mortality rate for salmeterol alone or fluticasone propionate alone did not differ significantly from that for placebo. As compared with placebo, the combination regimen reduced the annual rate of exacerbations from 1.13 to 0.85 and improved health status and spirometric values (P<0.001 for all comparisons with placebo). There was no difference in the incidence of ocular or bone side effects. The probability of having pneumonia reported as an adverse event was higher among patients receiving medications containing fluticasone propionate (19.6% in the combination-therapy group and 18.3% in the fluticasone group) than in the placebo group (12.3%, P<0.001 for comparisons between these treatments and placebo). CONCLUSIONS: The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance. There were significant benefits in all other outcomes among these patients. (ClinicalTrials.gov number, NCT00268216 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lung volumes and forced ventilatory flows
Quanjer, P. H., Tammeling, G. J., Cotes, J. E., Pedersen, O. F., Peslin, R., & Yernault, J.-C. (1993) · European Respiratory Journal · doi:10.1183/09041950.005s1693 · Cited by 5,318
(1993) · PubMed · Cited by 3,827
The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary Disease
Hogg, J. C., Chu, F., Utokaparch, S., Woods, R., Elliott, W. M., Buzatu, L., Cherniack, R. M., Rogers, R. M., Sciurba, F. C., Coxson, H. O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032158 · Cited by 3,782
NOCTURNAL OXYGEN THERAPY TRIAL GROUP* (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-3-391 · Cited by 2,218
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030287 · Cited by 2,071
Chronic obstructive pulmonary disease: current burden and future projections
Lopez, A. D., Shibuya, K., Rao, C., Mathers, C. D., Hansell, A. L., Held, L. S., Schmid, V., & Buist, S. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00025805 · Cited by 1,335
Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
LaRosa, J. C., He, J., & Vupputuri, S. (1999) · JAMA · doi:10.1001/jama.282.24.2340 · Cited by 1,246
The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality: A Randomized Clinical Trial
Anthonisen, N. R., Skeans, M. A., Wise, R. A., Manfreda, J., Kanner, R. E., Connett, J. E., & for the Lung Health Study Research Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-4-200502150-00005 · Cited by 1,237
Cited by
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Self-citationVogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0218pp · Cited by 3,187
Self-citationSusceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
Hurst, J. R., Vestbo, J., Anzueto, A., Locantore, N., Müllerova, H., Tal-Singer, R., Miller, B., Lomas, D. A., Agusti, A., MacNee, W., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909883 · Cited by 2,981
Self-citationZhou, Y., Wang, J., Gu, Z., Wang, S., Zhu, W., Aceña, J. L., Soloshonok, V. A., Izawa, K., & Liu, H. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00392 · Cited by 2,808
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Moore, W. C., Meyers, D. A., Wenzel, S. E., Teague, W. G., Li, H., Li, X., D'Agostino, R., Castro, M., Curran-Everett, D., Fitzpatrick, A. M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0896oc · Cited by 2,129
Tufford (2017) · doi:10.1007/s · Cited by 2,003
Systemic manifestations and comorbidities of COPD
Barnes, P. J., & Celli, B. R. (2009) · European Respiratory Journal · doi:10.1183/09031936.00128008 · Cited by 1,820
Self-citationCOPD exacerbations: Defining their cause and prevention
Wedzicha, J. A., & Seemungal, T. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61382-8 · Cited by 1,370
Azithromycin for prevention of exacerbations of COPD
Albert, R. K., Connett, J., Bailey, W. C., Casaburi, R., Cooper, J. A. D., Criner, G. J., Curtis, J. L., Dransfield, M. T., Han, M. K., Lazarus, S. C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104623 · Cited by 1,226
Qaseem, A., Wilt, T. J., Weinberger, S. E., Hanania, N. A., Criner, G., van der Molen, T., Marciniuk, D. D., Denberg, T., Schünemann, H., Wedzicha, W., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-3-201108020-00008 · Cited by 1,087
After asthma: redefining airways diseases
Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E., Brusselle, G., Cullinan, P., Custovic, A., Ducharme, F. M., Fahy, J. V., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)30879-6 · Cited by 1,073
Mortality in COPD: role of comorbidities
Sin, D. D., Anthonisen, N. R., Soriano, J. B., & Agusti, A. G. (2006) · European Respiratory Journal · doi:10.1183/09031936.00133805 · Cited by 1,052
Chronic obstructive pulmonary disease
Decramer, M., Janssens, W., & Miravitlles, M. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60968-9 · Cited by 972
Changes in Forced Expiratory Volume in 1 Second over Time in COPD
Vestbo, J., Edwards, L. D., Scanlon, P. D., Yates, J. C., Agusti, A., Bakke, P., Calverley, P. M. A., Celli, B., Coxson, H. O., Crim, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105482 · Cited by 963
Self-citationChronic obstructive pulmonary disease
Rabe, K. F., & Watz, H. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31222-9 · Cited by 960
Physical Activity Is the Strongest Predictor of All-Cause Mortality in Patients With COPD
Waschki, B., Kirsten, A., Holz, O., Müller, K.-C., Meyer, T., Watz, H., & Magnussen, H. (2011) · Chest · doi:10.1378/chest.10-2521 · Cited by 951
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00214-2017 · Cited by 881
Self-citationIndacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD
Wedzicha, J. A., Banerji, D., Chapman, K. R., Vestbo, J., Roche, N., Ayers, R. T., Thach, C., Fogel, R., Patalano, F., & Vogelmeier, C. F. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516385 · Cited by 844
Self-citationRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
Calverley, P. M., Rabe, K. F., Goehring, U.-M., Kristiansen, S., Fabbri, L. M., & Martinez, F. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61255-1 · Cited by 829
Self-citationWedzicha, J. A., Calverley, P. M. A., Seemungal, T. A., Hagan, G., Ansari, Z., & Stockley, R. A. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200707-973oc · Cited by 827
Self-citationSuissa, S., Dell'Aniello, S., & Ernst, P. (2012) · Thorax · doi:10.1136/thoraxjnl-2011-201518 · Cited by 779
Celli, B. R., Thomas, N. E., Anderson, J. A., Ferguson, G. T., Jenkins, C. R., Jones, P. W., Vestbo, J., Knobil, K., Yates, J. C., & Calverley, P. M. A. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200712-1869oc · Cited by 748
Self-citationMaki, R. G., Wathen, J. K., Patel, S. R., Priebat, D. A., Okuno, S. H., Samuels, B., Fanucchi, M., Harmon, D. C., Schuetze, S. M., Reinke, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4117 · Cited by 742
Chronic obstructive pulmonary disease
Barnes, P. J., Burney, P. G. J., Silverman, E. K., Celli, B. R., Vestbo, J., Wedzicha, J. A., & Wouters, E. F. M. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.76 · Cited by 734
Self-citationO’Donnell, D. E., Aaron, S., Bourbeau, J., Hernandez, P., Marciniuk, D. D., Balter, M., Ford, G., Gervais, A., Goldstein, R., Hodder, R., et al. (2007) · Canadian Respiratory Journal · doi:10.1155/2007/830570 · Cited by 693
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD
Rabe, K. F., Martinez, F. J., Ferguson, G. T., Wang, C., Singh, D., Wedzicha, J. A., Trivedi, R., St. Rose, E., Ballal, S., McLaren, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916046 · Cited by 690
Self-citationTiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
Vogelmeier, C., Hederer, B., Glaab, T., Schmidt, H., Rutten-van Mölken, M. P. M. H., Beeh, K. M., Rabe, K. F., & Fabbri, L. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008378 · Cited by 684
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · Respirology · doi:10.1111/resp.13012 · Cited by 681
Self-citationComplex chronic comorbidities of COPD
Fabbri, L. M., Luppi, F., Beghé, B., & Rabe, K. F. (2008) · European Respiratory Journal · doi:10.1183/09031936.00114307 · Cited by 660
Zhu, Y., Han, J., Wang, J., Shibata, N., Sodeoka, M., Soloshonok, V. A., Coelho, J. A. S., & Toste, F. D. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00778 · Cited by 640
From COPD to chronic systemic inflammatory syndrome?
Fabbri, L. M., & Rabe, K. F. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61383-x · Cited by 635
Fabbri, L. M., Calverley, P. M., Izquierdo-Alonso, J. L., Bundschuh, D. S., Brose, M., Martinez, F. J., & Rabe, K. F. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61252-6 · Cited by 614
Self-citationBafadhel, M., McKenna, S., Terry, S., Mistry, V., Pancholi, M., Venge, P., Lomas, D. A., Barer, M. R., Johnston, S. L., Pavord, I. D., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201108-1553oc · Cited by 612
Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD
Magnussen, H., Disse, B., Rodriguez-Roisin, R., Kirsten, A., Watz, H., Tetzlaff, K., Towse, L., Finnigan, H., Dahl, R., Decramer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407154 · Cited by 606
Self-citationMultifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction
Chung, K. F., & Adcock, I. M. (2008) · European Respiratory Journal · doi:10.1183/09031936.00018908 · Cited by 599
Wedzicha, J. A., Decramer, M., Ficker, J. H., Niewoehner, D. E., Sandström, T., Taylor, A. F., D'Andrea, P., Arrasate, C., Chen, H., & Banerji, D. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70052-3 · Cited by 535
Glucocorticosteroids: current and future directions
Barnes, P. J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01199.x · Cited by 533
Adherence to inhaled therapy, mortality and hospital admission in COPD
Vestbo, J., Anderson, J. A., Calverley, P. M. A., Celli, B., Ferguson, G. T., Jenkins, C., Knobil, K., Willits, L. R., Yates, J. C., & Jones, P. W. (2009) · Thorax · doi:10.1136/thx.2009.113662 · Cited by 516
Self-citationInhaled corticosteroids for stable chronic obstructive pulmonary disease
Yang, I. A., Clarke, M. S., Sim, E. H., & Fong, K. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002991.pub3 · Cited by 523
Puhan, M. A., Garcia-Aymerich, J., Frey, M., ter Riet, G., Antó, J. M., Agustí, A. G., Gómez, F. P., Rodríguez-Roisín, R., Moons, K. G., Kessels, A. G., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61301-5 · Cited by 521
Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision
Celli, B., Fabbri, L., Criner, G., Martinez, F. J., Mannino, D., Vogelmeier, C., Montes de Oca, M., Papi, A., Sin, D. D., Han, M. K., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202204-0671pp · Cited by 518
Self-citationIncreased Risk of Myocardial Infarction and Stroke Following Exacerbation of COPD
Donaldson, G. C., Hurst, J. R., Smith, C. J., Hubbard, R. B., & Wedzicha, J. A. (2010) · Chest · doi:10.1378/chest.09-2029 · Cited by 514
Chapman, K. R., Burdon, J. G. W., Piitulainen, E., Sandhaus, R. A., Seersholm, N., Stocks, J. M., Stoel, B. C., Huang, L., Yao, Z., Edelman, J. M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60860-1 · Cited by 514
Decramer, M., Celli, B., Kesten, S., Lystig, T., Mehra, S., & Tashkin, D. P. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61298-8 · Cited by 495
Self-citationVestbo, J., Anderson, J. A., Brook, R. D., Calverley, P. M. A., Celli, B. R., Crim, C., Martinez, F., Yates, J., & Newby, D. E. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30069-1 · Cited by 483
Self-citationComorbidities in Chronic Obstructive Pulmonary Disease
Chatila, W. M., Thomashow, B. M., Minai, O. A., Criner, G. J., & Make, B. J. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200709-148et · Cited by 478
Pharmacology and Therapeutics of Bronchodilators
Cazzola, M., Page, C. P., Calzetta, L., & Matera, M. G. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004580 · Cited by 467
Exacerbations of chronic obstructive pulmonary disease
Celli, B. R., & Barnes, P. J. (2007) · European Respiratory Journal · doi:10.1183/09031936.00109906 · Cited by 462
Self-citationUpdate on Clinical Aspects of Chronic Obstructive Pulmonary Disease
Celli, B. R., & Wedzicha, J. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1900500 · Cited by 461
Self-citationHan, M. K., Kazerooni, E. A., Lynch, D. A., Liu, L. X., Murray, S., Curtis, J. L., Criner, G. J., Kim, V., Bowler, R. P., Hanania, N. A., et al. (2011) · Radiology · doi:10.1148/radiol.11110173 · Cited by 453
Feary, J. R., Rodrigues, L. C., Smith, C. J., Hubbard, R. B., & Gibson, J. E. (2010) · Thorax · doi:10.1136/thx.2009.128082 · Cited by 445
Inhaled corticosteroids in COPD and the risk of serious pneumonia
Suissa, S., Patenaude, V., Lapi, F., & Ernst, P. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202872 · Cited by 444
Seemungal, T. A. R., Wilkinson, T. M. A., Hurst, J. R., Perera, W. R., Sapsford, R. J., & Wedzicha, J. A. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200801-145oc · Cited by 444
Celli, B. R., Locantore, N., Yates, J., Tal-Singer, R., Miller, B. E., Bakke, P., Calverley, P., Coxson, H., Crim, C., Edwards, L. D., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201110-1792oc · Cited by 432
Self-citationCrim, C., Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Willits, L. R., Yates, J. C., & Vestbo, J. (2009) · European Respiratory Journal · doi:10.1183/09031936.00193908 · Cited by 432
Self-citationThe clinical and economic burden of chronic obstructive pulmonary disease in the USA
Ray, S., Guarascio, Finch, & Self, T. (2013) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s34321 · Cited by 425
Singh, D., Papi, A., Corradi, M., Pavlišová, I., Montagna, I., Francisco, C., Cohuet, G., Vezzoli, S., Scuri, M., & Vestbo, J. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31354-x · Cited by 425
Self-citationBowerman, K. L., Rehman, S. F., Vaughan, A., Lachner, N., Budden, K. F., Kim, R. Y., Wood, D. L. A., Gellatly, S. L., Shukla, S. D., Wood, L. G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19701-0 · Cited by 425
Qaseem, A., Snow, V., Shekelle, P., Sherif, K., Wilt, T. J., Weinberger, S., Owens, D. K., & for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians* (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00008 · Cited by 424
Molecular and cellular mechanisms of pulmonary fibrosis
Todd, N. W., Luzina, I. G., & Atamas, S. P. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-11 · Cited by 418
Mallia, P., Message, S. D., Gielen, V., Contoli, M., Gray, K., Kebadze, T., Aniscenko, J., Laza-Stanca, V., Edwards, M. R., Slater, L., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0833oc · Cited by 415
Mechanistic links between COPD and lung cancer
Houghton, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3477 · Cited by 414
Cardiovascular disease and COPD: dangerous liaisons?
Rabe, K. F., Hurst, J. R., & Suissa, S. (2018) · European Respiratory Review · doi:10.1183/16000617.0057-2018 · Cited by 410
Wallmeier, J., Nielsen, K. G., Kuehni, C. E., Lucas, J. S., Leigh, M. W., Zariwala, M. A., & Omran, H. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0209-6 · Cited by 403
Welte, T., Miravitlles, M., Hernandez, P., Eriksson, G., Peterson, S., Polanowski, T., & Kessler, R. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200904-0492oc · Cited by 408
Medication adherence issues in patients treated for COPD
Restrepo, R. (2008) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s3036 · Cited by 407
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Kew, K. M., & Seniukovich, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010115.pub2 · Cited by 398
Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS): Table 1
Couper, D., LaVange, L. M., Han, M., Barr, R. G., Bleecker, E., Hoffman, E. A., Kanner, R., Kleerup, E., Martinez, F. J., Woodruff, P. G., et al. (2014) · Thorax · doi:10.1136/thoraxjnl-2013-203897 · Cited by 394
Gibson, P. G., McDonald, V. M., & Marks, G. B. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61087-2 · Cited by 394
Ernst, P., Gonzalez, A. V., Brassard, P., & Suissa, S. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200611-1630oc · Cited by 389
Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study
Bateman, E. D., Ferguson, G. T., Barnes, N., Gallagher, N., Green, Y., Henley, M., & Banerji, D. (2013) · European Respiratory Journal · doi:10.1183/09031936.00200212 · Cited by 388
Self-citationFerguson, G. T., Rabe, K. F., Martinez, F. J., Fabbri, L. M., Wang, C., Ichinose, M., Bourne, E., Ballal, S., Darken, P., DeAngelis, K., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30327-8 · Cited by 379
Self-citationMiravitlles, M., Soler-Cataluña, J. J., Calle, M., Molina, J., Almagro, P., Quintano, J. A., Trigueros, J. A., Cosío, B. G., Casanova, C., Antonio Riesco, J., et al. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2017.03.018 · Cited by 378
Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease
Edwards, M. R., Bartlett, N. W., Clarke, D., Birrell, M., Belvisi, M., & Johnston, S. L. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.003 · Cited by 375
Martinez, F. J., Calverley, P. M. A., Goehring, U.-M., Brose, M., Fabbri, L. M., & Rabe, K. F. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62410-7 · Cited by 374
Self-citationWhat is asthma−COPD overlap syndrome? Towards a consensus definition from a round table discussion
Sin, D. D., Miravitlles, M., Mannino, D. M., Soriano, J. B., Price, D., Celli, B. R., Leung, J. M., Nakano, Y., Park, H. Y., Wark, P. A., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00436-2016 · Cited by 367
Self-citationDrummond, M. B., Dasenbrook, E. C., Pitz, M. W., Murphy, D. J., & Fan, E. (2008) · JAMA · doi:10.1001/jama.2008.717 · Cited by 364
Lehouck, A., Mathieu, C., Carremans, C., Baeke, F., Verhaegen, J., Van Eldere, J., Decallonne, B., Bouillon, R., Decramer, M., & Janssens, W. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-2-201201170-00004 · Cited by 363
Screening for and early detection of chronic obstructive pulmonary disease
Soriano, J. B., Zielinski, J., & Price, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61290-3 · Cited by 362
Zheng, J.-P., Kang, J., Huang, S.-G., Chen, P., Yao, W.-Z., Yang, L., Bai, C.-X., Wang, C.-Z., Wang, C., Chen, B.-Y., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60869-7 · Cited by 358
Clinical COPD phenotypes: a novel approach using principal component and cluster analyses
Burgel, P.-R., Paillasseur, J.-L., Caillaud, D., Tillie-Leblond, I., Chanez, P., Escamilla, R., Court-Fortune, I., Perez, T., Carré, P., & Roche, N. (2010) · European Respiratory Journal · doi:10.1183/09031936.00175109 · Cited by 358
Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease: Indacaterol Versus Tiotropium
Donohue, J. F., Fogarty, C., Lötvall, J., Mahler, D. A., Worth, H., Yorgancioğlu, A., Iqbal, A., Swales, J., Owen, R., Higgins, M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200910-1500oc · Cited by 358
New evidence of risk factors for community-acquired pneumonia: a population-based study
Almirall, J., Bolíbar, I., Serra-Prat, M., Roig, J., Hospital, I., Carandell, E., Agustí, M., Ayuso, P., Estela, A., Torres, A., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00095807 · Cited by 354
Impact of exacerbations on COPD
Anzueto, A. (2010) · European Respiratory Review · doi:10.1183/09059180.00002610 · Cited by 353
To, Y., Ito, K., Kizawa, Y., Failla, M., Ito, M., Kusama, T., Elliott, W. M., Hogg, J. C., Adcock, I. M., & Barnes, P. J. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0937oc · Cited by 352
Singh, S., Amin, A. V., & Loke, Y. K. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.550 · Cited by 346
Jenkins, C. R., Jones, P. W., Calverley, P. M., Celli, B., Anderson, J. A., Ferguson, G. T., Yates, J. C., Willits, L. R., & Vestbo, J. (2009) · Respiratory Research · doi:10.1186/1465-9921-10-59 · Cited by 345
Self-citationDransfield, M. T., Bourbeau, J., Jones, P. W., Hanania, N. A., Mahler, D. A., Vestbo, J., Wachtel, A., Martinez, F. J., Barnhart, F., Sanford, L., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70040-7 · Cited by 345
Self-citationAnnual Change in Pulmonary Function and Clinical Phenotype in Chronic Obstructive Pulmonary Disease
Nishimura, M., Makita, H., Nagai, K., Konno, S., Nasuhara, Y., Hasegawa, M., Shimizu, K., Betsuyaku, T., Ito, Y. M., Fuke, S., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201106-0992oc · Cited by 344
Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis
Andréjak, C., Nielsen, R., Thomsen, V. Ø., Duhaut, P., Sørensen, H. T., & Thomsen, R. W. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-201772 · Cited by 340
Tiotropium Respimat Inhaler and the Risk of Death in COPD
Wise, R. A., Anzueto, A., Cotton, D., Dahl, R., Devins, T., Disse, B., Dusser, D., Joseph, E., Kattenbeck, S., Koenen-Bergmann, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303342 · Cited by 333
Self-citationMehta, M., Dhanjal, D. S., Paudel, K. R., Singh, B., Gupta, G., Rajeshkumar, S., Thangavelu, L., Tambuwala, M. M., Bakshi, H. A., Chellappan, D. K., et al. (2020) · Inflammopharmacology · doi:10.1007/s10787-020-00698-3 · Cited by 330
Hatzelmann, A., Morcillo, E. J., Lungarella, G., Adnot, S., Sanjar, S., Beume, R., Schudt, C., & Tenor, H. (2010) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2010.03.011 · Cited by 320
Role of HDAC2 in the Pathophysiology of COPD
Barnes, P. J. (2009) · Annual Review of Physiology · doi:10.1146/annurev.physiol.010908.163257 · Cited by 318
Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression
Suissa, S., Kezouh, A., & Ernst, P. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.06.019 · Cited by 317
Brightling, C. E., Bleecker, E. R., Panettieri, R. A., Bafadhel, M., She, D., Ward, C. K., Xu, X., Birrell, C., & van der Merwe, R. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70187-0 · Cited by 315
Vogelmeier, C. F., Bateman, E. D., Pallante, J., Alagappan, V. K., D'Andrea, P., Chen, H., & Banerji, D. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(12)70052-8 · Cited by 314
Vogelmeier, C. F., Criner, G. J., Martínez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2017.02.001 · Cited by 309
Self-citationRutten, F. H. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.112 · Cited by 307
Metadata
- Authors
- Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Yates, J. C., & Vestbo, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-02-22
- Volume
- 356
- Issue
- 8
- Pages
- 775-789
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2142724633
- Cited by
- 3,248
- References
- 26
- FWCI
- 222.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.